Table 2 Data on prior asthma medication, lung function, patient-recorded outcomes and healthcare utilization recorded before the start of benralizumab therapy (i.e., at the index date or during the 12 months prior to the index date)
Characteristics | Evaluable population N = 205 |
|---|---|
Corticosteroid use at the index date | |
ICS/LABA or ICS + LABA | |
Any ICS dose | 205 (100%) |
Low ICS dose | 3 (1.5%) |
Low/Medium ICS dose | 16 (7.8%) |
Medium ICS dose | 6 (2.9%) |
High ICS dose | 179 (87.3%) |
Data unknown | 1 (0.5%) |
LAMA | 104 (50.7%) |
Other* | 88 (42.9%) |
OCS | 53 (25.9%) |
OCS dosage among users, prednisone-equivalent, mg/die (N = 48) | 10 (5–25) |
Biologic use during the 12 months prior to the index date | |
Yes, any biologic | 58 (28.3%) |
Omalizumab | 34 (16.6%) |
Mepolizumab | 19 (9.3%) |
Omalizumab > Mepolizumab | 5 (2.4%) |
No | 147 (71.7%) |
Lung function at the index date | |
Pre-bronchodilator FEV1, L (N = 154) | 2.0 ± 0.8 |
Post-bronchodilator FEV1, L (N = 92) | 2.1 ± 0.9 |
Pre-bronchodilator FEV1, % predicted (N = 159) | 70.6 ± 21.6 |
Post-bronchodilator FEV1, % predicted (N = 90) | 75.3 ± 22.9 |
Pre-bronchodilator FVC, L (N = 148) | 3.0 ± 1.0 |
FeNO, ppb (N = 66) | 46.7 ± 34.6 |
ACT score at the index date (N = 161) | 14.7 ± 4.7 |
AQLQ score at the index date (N = 32) | 3.7 ± 1.2 |
Healthcare resource utilization for asthma per patient during the 12 months prior to the index date (N = 189) | |
Primary care physician/GP office visits | 1.0 ± 2.0 |
Specialist visits | 2.4 ± 3.0 |
ED admissions | 0.2 ± 0.5 |
Hospitalizations | 0.1 ± 0.4 |